In vitro antimicrobial activity of balofloxacin and its therapeutic efficacy in respiratory infections

M. Tateyama, H. Fukuhara, Y. Irabu, J. Inadome, M. Gaja, H. Nakamura, H. Kaneshima, A. Saito, Nobuchika Kusano, I. Nakasone

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

We performed measured laboratory and clinical studies on balofloxacin (BLFX), a new oral pyridone-carboxylic acid derivative. 1) Laboratory activity. The minimum inhibitory concentrations (MICs) of BLFX for a total of 397 strains clinically isolated and 41 standard strains of Legionella spp. were determined and compared with those of tosufloxacin (TFLX), ofloxacin (OFLX), ciprofloxacin (CPFX), and sparfloxacin (SPFX). BLFX proved to have a broad antibacterial spectrum, and its in vitro activity against gram-positive cocci, especially MRSA, was more potent than that of the other four reference quinolones. Against gram-negative bacilli, the in vitro activity of BLFX was the same or slightly lower than that of the other drugs. 2) Clinical efficacy. We administered BLFX to ten patients with respiratory tract infections (bronchopneumonia: 3 cases, acute exacerbation of COPD: 4 cases, acute exacerbation of bronchiectasis: 1 case, mycoplasmal pneumonia: 2 cases) at a dose of 200~400 mg daily for 7 to 14 days. The clinical efficacy was excellent in 3 cases and good in 7. Causative bacteria were Streptococcus pneumoniae (2 cases), Haemophilus influenzae (1 case), Klebsiella pneumoniae (1 case), Enterobacter cloacae (1 case). All 5 strains were eradicated. No side effects were observed in any patient, for an efficacy rate of 100%. As for abnormal laboratory findings, elevation of eosinophillia, transaminase and transaminase and ALP were observed in 1 case, 2 and 1 respectively but they were all mild and transient.

Original languageEnglish
Pages (from-to)281-287
Number of pages7
JournalJapanese Journal of Chemotherapy
Volume43
Issue numberSUPPL. 5
Publication statusPublished - 1995
Externally publishedYes

Fingerprint

Respiratory Tract Infections
tosufloxacin
Transaminases
Pyridones
Therapeutics
Enterobacter cloacae
Bronchopneumonia
Gram-Positive Cocci
Legionella
Ofloxacin
Bronchiectasis
Quinolones
Haemophilus influenzae
Klebsiella pneumoniae
Microbial Sensitivity Tests
Methicillin-Resistant Staphylococcus aureus
Ciprofloxacin
Carboxylic Acids
Streptococcus pneumoniae
Chronic Obstructive Pulmonary Disease

Keywords

  • balofloxacin

ASJC Scopus subject areas

  • Pharmacology

Cite this

Tateyama, M., Fukuhara, H., Irabu, Y., Inadome, J., Gaja, M., Nakamura, H., ... Nakasone, I. (1995). In vitro antimicrobial activity of balofloxacin and its therapeutic efficacy in respiratory infections. Japanese Journal of Chemotherapy, 43(SUPPL. 5), 281-287.

In vitro antimicrobial activity of balofloxacin and its therapeutic efficacy in respiratory infections. / Tateyama, M.; Fukuhara, H.; Irabu, Y.; Inadome, J.; Gaja, M.; Nakamura, H.; Kaneshima, H.; Saito, A.; Kusano, Nobuchika; Nakasone, I.

In: Japanese Journal of Chemotherapy, Vol. 43, No. SUPPL. 5, 1995, p. 281-287.

Research output: Contribution to journalArticle

Tateyama, M, Fukuhara, H, Irabu, Y, Inadome, J, Gaja, M, Nakamura, H, Kaneshima, H, Saito, A, Kusano, N & Nakasone, I 1995, 'In vitro antimicrobial activity of balofloxacin and its therapeutic efficacy in respiratory infections', Japanese Journal of Chemotherapy, vol. 43, no. SUPPL. 5, pp. 281-287.
Tateyama M, Fukuhara H, Irabu Y, Inadome J, Gaja M, Nakamura H et al. In vitro antimicrobial activity of balofloxacin and its therapeutic efficacy in respiratory infections. Japanese Journal of Chemotherapy. 1995;43(SUPPL. 5):281-287.
Tateyama, M. ; Fukuhara, H. ; Irabu, Y. ; Inadome, J. ; Gaja, M. ; Nakamura, H. ; Kaneshima, H. ; Saito, A. ; Kusano, Nobuchika ; Nakasone, I. / In vitro antimicrobial activity of balofloxacin and its therapeutic efficacy in respiratory infections. In: Japanese Journal of Chemotherapy. 1995 ; Vol. 43, No. SUPPL. 5. pp. 281-287.
@article{a8d9cb03f4674f34ae9da3d0f97faab8,
title = "In vitro antimicrobial activity of balofloxacin and its therapeutic efficacy in respiratory infections",
abstract = "We performed measured laboratory and clinical studies on balofloxacin (BLFX), a new oral pyridone-carboxylic acid derivative. 1) Laboratory activity. The minimum inhibitory concentrations (MICs) of BLFX for a total of 397 strains clinically isolated and 41 standard strains of Legionella spp. were determined and compared with those of tosufloxacin (TFLX), ofloxacin (OFLX), ciprofloxacin (CPFX), and sparfloxacin (SPFX). BLFX proved to have a broad antibacterial spectrum, and its in vitro activity against gram-positive cocci, especially MRSA, was more potent than that of the other four reference quinolones. Against gram-negative bacilli, the in vitro activity of BLFX was the same or slightly lower than that of the other drugs. 2) Clinical efficacy. We administered BLFX to ten patients with respiratory tract infections (bronchopneumonia: 3 cases, acute exacerbation of COPD: 4 cases, acute exacerbation of bronchiectasis: 1 case, mycoplasmal pneumonia: 2 cases) at a dose of 200~400 mg daily for 7 to 14 days. The clinical efficacy was excellent in 3 cases and good in 7. Causative bacteria were Streptococcus pneumoniae (2 cases), Haemophilus influenzae (1 case), Klebsiella pneumoniae (1 case), Enterobacter cloacae (1 case). All 5 strains were eradicated. No side effects were observed in any patient, for an efficacy rate of 100{\%}. As for abnormal laboratory findings, elevation of eosinophillia, transaminase and transaminase and ALP were observed in 1 case, 2 and 1 respectively but they were all mild and transient.",
keywords = "balofloxacin",
author = "M. Tateyama and H. Fukuhara and Y. Irabu and J. Inadome and M. Gaja and H. Nakamura and H. Kaneshima and A. Saito and Nobuchika Kusano and I. Nakasone",
year = "1995",
language = "English",
volume = "43",
pages = "281--287",
journal = "Japanese Journal of Chemotherapy",
issn = "1340-7007",
publisher = "Japan Society of Chemotherapy",
number = "SUPPL. 5",

}

TY - JOUR

T1 - In vitro antimicrobial activity of balofloxacin and its therapeutic efficacy in respiratory infections

AU - Tateyama, M.

AU - Fukuhara, H.

AU - Irabu, Y.

AU - Inadome, J.

AU - Gaja, M.

AU - Nakamura, H.

AU - Kaneshima, H.

AU - Saito, A.

AU - Kusano, Nobuchika

AU - Nakasone, I.

PY - 1995

Y1 - 1995

N2 - We performed measured laboratory and clinical studies on balofloxacin (BLFX), a new oral pyridone-carboxylic acid derivative. 1) Laboratory activity. The minimum inhibitory concentrations (MICs) of BLFX for a total of 397 strains clinically isolated and 41 standard strains of Legionella spp. were determined and compared with those of tosufloxacin (TFLX), ofloxacin (OFLX), ciprofloxacin (CPFX), and sparfloxacin (SPFX). BLFX proved to have a broad antibacterial spectrum, and its in vitro activity against gram-positive cocci, especially MRSA, was more potent than that of the other four reference quinolones. Against gram-negative bacilli, the in vitro activity of BLFX was the same or slightly lower than that of the other drugs. 2) Clinical efficacy. We administered BLFX to ten patients with respiratory tract infections (bronchopneumonia: 3 cases, acute exacerbation of COPD: 4 cases, acute exacerbation of bronchiectasis: 1 case, mycoplasmal pneumonia: 2 cases) at a dose of 200~400 mg daily for 7 to 14 days. The clinical efficacy was excellent in 3 cases and good in 7. Causative bacteria were Streptococcus pneumoniae (2 cases), Haemophilus influenzae (1 case), Klebsiella pneumoniae (1 case), Enterobacter cloacae (1 case). All 5 strains were eradicated. No side effects were observed in any patient, for an efficacy rate of 100%. As for abnormal laboratory findings, elevation of eosinophillia, transaminase and transaminase and ALP were observed in 1 case, 2 and 1 respectively but they were all mild and transient.

AB - We performed measured laboratory and clinical studies on balofloxacin (BLFX), a new oral pyridone-carboxylic acid derivative. 1) Laboratory activity. The minimum inhibitory concentrations (MICs) of BLFX for a total of 397 strains clinically isolated and 41 standard strains of Legionella spp. were determined and compared with those of tosufloxacin (TFLX), ofloxacin (OFLX), ciprofloxacin (CPFX), and sparfloxacin (SPFX). BLFX proved to have a broad antibacterial spectrum, and its in vitro activity against gram-positive cocci, especially MRSA, was more potent than that of the other four reference quinolones. Against gram-negative bacilli, the in vitro activity of BLFX was the same or slightly lower than that of the other drugs. 2) Clinical efficacy. We administered BLFX to ten patients with respiratory tract infections (bronchopneumonia: 3 cases, acute exacerbation of COPD: 4 cases, acute exacerbation of bronchiectasis: 1 case, mycoplasmal pneumonia: 2 cases) at a dose of 200~400 mg daily for 7 to 14 days. The clinical efficacy was excellent in 3 cases and good in 7. Causative bacteria were Streptococcus pneumoniae (2 cases), Haemophilus influenzae (1 case), Klebsiella pneumoniae (1 case), Enterobacter cloacae (1 case). All 5 strains were eradicated. No side effects were observed in any patient, for an efficacy rate of 100%. As for abnormal laboratory findings, elevation of eosinophillia, transaminase and transaminase and ALP were observed in 1 case, 2 and 1 respectively but they were all mild and transient.

KW - balofloxacin

UR - http://www.scopus.com/inward/record.url?scp=0029559540&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029559540&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0029559540

VL - 43

SP - 281

EP - 287

JO - Japanese Journal of Chemotherapy

JF - Japanese Journal of Chemotherapy

SN - 1340-7007

IS - SUPPL. 5

ER -